---
title: "ADC awards retention incentives to CEO Ameet Mallik, CFO Jose Carmona and CMO Mohamed Zaki"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291591043.md"
description: "ADC Therapeutics granted one-time retention awards to CEO Ameet Mallik, CFO Jose Carmona, and CMO Mohamed Zaki. The awards include cash incentives and Restricted Stock Units (RSUs) with vesting conditions tied to June 30, 2027, or earlier termination without cause/for good reason. Cash components are repayable if employment ends before the vesting date under specific circumstances. These measures were approved by the Board to retain key leadership."
datetime: "2026-07-02T21:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291591043.md)
  - [en](https://longbridge.com/en/news/291591043.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291591043.md)
---

# ADC awards retention incentives to CEO Ameet Mallik, CFO Jose Carmona and CMO Mohamed Zaki

**ADC granted one-time retention awards to CEO Ameet Mallik, CFO Jose Carmona and CMO Mohamed Zaki, including cash and RSU components with specified vesting and repayment terms.**

Individual

Ameet Mallik

Jose Carmona

Mohamed Zaki

Role

Chief Executive Officer

Chief Financial Officer

Chief Medical Officer

Type of Change

Retention award granted

Retention award granted

Retention award granted

Effective Date

June 30, 2026 (RSUs); cash paid on or about July 15, 2026

June 30, 2026 (RSUs); cash paid on or about July 15, 2026

June 30, 2026 (RSUs); cash paid on or about July 15, 2026

Reason

One-time retention award approved by Board

One-time retention award approved by Board

One-time retention award approved by Board

Replacement Info

Not disclosed

Not disclosed

Not disclosed

Background Details

Cash incentive $1,795,500; RSUs 675,000; RSUs vest on earlier of June 30, 2027 or termination by Company without cause/for good reason; cash repayable if employment ends before June 30, 2027 except for specified terminations

Cash incentive $541,842; RSUs 203,700; RSUs vest on earlier of June 30, 2027 or termination by Company without cause/for good reason; cash repayable if employment ends before June 30, 2027 except for specified terminations

Cash incentive $568,974; RSUs 213,900; RSUs vest on earlier of June 30, 2027 or termination by Company without cause/for good reason; cash repayable if employment ends before June 30, 2027 except for specified terminations

Board/Committee Role Changes

Not disclosed

Not disclosed

Not disclosed

Original SEC Filing: ADC Therapeutics SA \[ ADCT \] - 8-K - Jul. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL](https://longbridge.com/en/news/291272696.md)
- [Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway](https://longbridge.com/en/news/294417283.md)
- [Chemed Q2 revenue beats estimates, helped by VITAS segment growth](https://longbridge.com/en/news/294109919.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)